Drugs / Multimeric-001
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01010737 | Sep 2009 → Mar 2010 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT00877448 | Jun → Oct 2009 | — | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03058692 | Apr 2018 → Jan 2019 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02691130 | Nov 2015 → Oct 2016 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02293317 | Nov 2014 → Mar 2015 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01419925 | Aug 2011 → Jan 2012 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01146119 | Jul 2010 → May 2011 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03450915 | Aug 2018 → Jul 2020 | influenza | BiondVax Pharmaceuticals ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multimeric-001 | “Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine” NCT03058692 ↗ |
| Known as | M-001 | “A new vaccine, "Multimeric-001" (M-001) has been recently developed, containing conserved, common linear influenza epitopes that activate both cellular and humoral arms of the...” PMID 25173483 ↗ Aug 20145“Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization.” NCT01010737 ↗ “The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein.” NCT03058692 ↗ “Multimeric 001 (M-001)” NCT02691130 ↗ |
| Modality | Vaccine | “A new vaccine, Multimeric-001, containing conserved linear epitopes from the HA, NP, and M1 proteins of influenza type A and type B strains was designed to protect against...” PMID 22318394 ↗ Feb 2012 |
| Route | Intramuscular | “Two intramuscular injections were administered, 21 days apart.” PMID 22318394 ↗ Feb 2012 |